

Remarks

Claims 29-32 are pending in the application. Pursuant to the RCE filed herewith, the amendments set forth in the amendment documents filed April 20, 2005 and May 6, 2005 are deemed to have been entered. The claims are further amended herein, including the cancellation of claims 28 and 33-35.

The specification has been amended as suggested by Examiner to overcome the rejection of claim 31.

Claim 28 has been rejected under 35 U.S.C. 102 as anticipated by Landry *et al.* Claim 28 has been cancelled, along with claims 33-35 that depend from it.

Claim 32 has been rejected over Landry *et al.* Claim 32 has been amended to change the minimum dosage to 50 mg, overcoming the rejection. Support for the amendment is found in the specification at page 13, line 25. The claim has been further amended to recite a therapeutic objective (“treating convulsions or seizures”) and a host receiving the treatment (“a patient”), overcoming the informalities noted by Examiner.

The application is believed to be in condition for allowance. An early action toward that end is earnestly solicited.

Respectfully submitted,

BY 
DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103
Telephone: (215) 988-3312
Fax: (215) 988-2757
Attorney for Applicants